Evidence map›Paper›PMID 38834551›Full record

ArticleCell discovery2024

Specialized Tfh cell subsets driving type-1 and type-2 humoral responses in lymphoid tissue.

Saumya Kumar, Afonso P Basto, Filipa Ribeiro, Silvia C P Almeida, Patricia Campos, Carina Peres, Nadia Pulvirenti, Sarwah Al-Khalidi, Anna Kilbey, Jimena Tosello and 8 more

Abstract read
In one paragraph

Article in Cell discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. TOX drives CD4Nature immunology · 2026
    Article
  5. Aging restricts maturation of CXCL13bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Circulating TFH2 Cell Expansion and GZMKJournal of asthma and allergy · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Cytotoxic CD4Frontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Saumya Kumar *Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Afonso P Basto *Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Filipa RibeiroInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Silvia C P AlmeidaInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Patricia CamposInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Carina PeresResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa, Portugal.
Nadia PulvirentiIstituto Nazionale di Genetica Molecolare, Milano, Italy.
Sarwah Al-KhalidiInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Anna KilbeyInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Jimena ToselloInstitut Curie, PSL Research University, INSERM U932, Paris, France.
Eliane PiaggioInstitut Curie, PSL Research University, INSERM U932, Paris, France.
Momtchilo RussoInstitute of Biomedical Sciences, Department of Immunology, University of Sao Paulo, Sao Paulo, Brazil.
Margarida Gama-CarvalhoBioISI - Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.
Seth B CoffeltInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0003-2257-2862
Ed W RobertsInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0002-8229-1715
Jens GeginatIstituto Nazionale di Genetica Molecolare, Milano, Italy.
Helena F FlorindoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa, Portugal.
Luis GracaInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. lgraca@medicina.ulisboa.pt.ORCID http://orcid.org/0000-0001-6935-8500

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) Enlght-ten 675395"la Caixa" Foundation (Caixa Foundation) HR22-00741
6 · The paper itself

Abstract

Effective antibody responses are essential to generate protective humoral immunity. Different inflammatory signals polarize T cells towards appropriate effector phenotypes during an infection or immunization. Th1 and Th2 cells have been associated with the polarization of humoral responses. However, T follicular helper cells (Tfh) have a unique ability to access the B cell follicle and support the germinal center (GC) responses by providing B cell help. We investigated the specialization of Tfh cells induced under type-1 and type-2 conditions. We first studied homogenous Tfh cell populations generated by adoptively transferred TCR-transgenic T cells in mice immunized with type-1 and type-2 adjuvants. Using a machine learning approach, we established a gene expression signature that discriminates Tfh cells polarized towards type-1 and type-2 response, defined as Tfh1 and Tfh2 cells. The distinct signatures of Tfh1 and Tfh2 cells were validated against datasets of Tfh cells induced following lymphocytic choriomeningitis virus (LCMV) or helminth infection. We generated single-cell and spatial transcriptomics datasets to dissect the heterogeneity of Tfh cells and their localization under the two immunizing conditions. Besides a distinct specialization of GC Tfh cells under the two immunizations and in different regions of the lymph nodes, we found a population of Gzmk

Identifiers

PMID38834551
PMCPMC11150427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.